225 related articles for article (PubMed ID: 1797561)
21. CCKB receptor activation results in increased [3H]thymidine incorporation in rat glioma C6 cells.
Kaufmann R; Henklein P; Nowak G
Neuropeptides; 1995 Nov; 29(5):241-4. PubMed ID: 8587658
[TBL] [Abstract][Full Text] [Related]
22. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
O'Neill MF; Dourish CT; Iversen SD
Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a gastrin-type receptor on rabbit gastric parietal cells using L365,260 and L364,718.
Roche S; Bali JP; Galleyrand JC; Magous R
Am J Physiol; 1991 Feb; 260(2 Pt 1):G182-8. PubMed ID: 1996638
[TBL] [Abstract][Full Text] [Related]
24. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice.
Derrien M; Noble F; Maldonado R; Roques BP
Neurosci Lett; 1993 Oct; 160(2):193-6. PubMed ID: 8247353
[TBL] [Abstract][Full Text] [Related]
25. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
[TBL] [Abstract][Full Text] [Related]
26. Cholecystokinin increases intracellular Ca2+ concentration in the Human JURKAT T Lymphocyte cell line.
Lignon MF; Bernad N; Martinez J
Eur J Pharmacol; 1993 May; 245(3):241-6. PubMed ID: 8335062
[TBL] [Abstract][Full Text] [Related]
27. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
Boyle SJ; Tang KW; Woodruff GN; McKnight AT
Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
[TBL] [Abstract][Full Text] [Related]
28. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
Ballaz S; Barber A; Fortuño A; Del Río J; Martin-Martínez M; Gómez-Monterrey I; Herranz R; González-Muñiz R; García-López MT
Br J Pharmacol; 1997 Jun; 121(4):759-67. PubMed ID: 9208145
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of CCK-B receptors involved in animal models of anxiety.
Derrien M; McCort-Tranchepain I; Ducos B; Roques BP; Durieux C
Pharmacol Biochem Behav; 1994 Sep; 49(1):133-41. PubMed ID: 7816864
[TBL] [Abstract][Full Text] [Related]
32. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314
[TBL] [Abstract][Full Text] [Related]
33. Enzyme-resistant CCK analogs with high affinities for central receptors.
Charpentier B; Durieux C; Pelaprat D; Dor A; Reibaud M; Blanchard JC; Roques BP
Peptides; 1988; 9(4):835-41. PubMed ID: 3226959
[TBL] [Abstract][Full Text] [Related]
34. "Gastrin" and "CCK" receptors on histamine- and somatostatin-containing cells from rabbit fundic mucosa-II. Characterization by means of selective antagonists (L-364,718 and L-365,260).
Roche S; Gusdinar T; Bali JP; Magous R
Biochem Pharmacol; 1991 Jul; 42(4):771-6. PubMed ID: 1714276
[TBL] [Abstract][Full Text] [Related]
35. Characterization of [3H](+/-)L-364,718 binding to solubilized cholecystokinin (CCK) receptors of rat pancreas.
Chang RS; Lotti VJ; Chen TB
Biochem Pharmacol; 1987 May; 36(10):1709-14. PubMed ID: 3593394
[TBL] [Abstract][Full Text] [Related]
36. Peripheral cholecystokinin type A receptors mediate oxytocin secretion in vivo.
Miller TR; Bianchi BR; Witte DG; Lin CW
Regul Pept; 1993 Jan; 43(1-2):107-12. PubMed ID: 8426907
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological studies on CCKB receptors in guinea pig synaptoneurosomes.
Galas MC; Bernad N; Martinez J
Eur J Pharmacol; 1992 May; 226(1):35-41. PubMed ID: 1327841
[TBL] [Abstract][Full Text] [Related]
38. Opposing effects of two CCK(B) agonists on the retrieval phase of a two-trial memory task after systemic injection in the rat.
Léna I; Simon H; Roques BP; Daugé V
Neuropharmacology; 1999 Apr; 38(4):543-53. PubMed ID: 10221758
[TBL] [Abstract][Full Text] [Related]
39. Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors.
Dourish CT; Rycroft W; Iversen SD
Science; 1989 Sep; 245(4925):1509-11. PubMed ID: 2781294
[TBL] [Abstract][Full Text] [Related]
40. Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system.
Hernando F; Fuentes JA; Fournié-Zaluski MC; Roques BP; Ruiz-Gayo M
Eur J Pharmacol; 1996 Dec; 318(2-3):221-9. PubMed ID: 9016909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
